{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T20:47:38Z","timestamp":1761338858825,"version":"3.44.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1016\/j.amjmed.2005.01.029","type":"journal-article","created":{"date-parts":[[2005,4,29]],"date-time":"2005-04-29T07:54:16Z","timestamp":1114761256000},"page":"515-520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Infliximab therapy in established rheumatoid arthritis: An observational study"],"prefix":"10.1016","volume":"118","author":[{"given":"Paraskevi V.","family":"Voulgari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannis","family":"Alamanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyros N.","family":"Nikas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios V.","family":"Bougias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Themistoklis I.","family":"Temekonidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros A.","family":"Drosos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2005.01.029_bib1","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJM199005033221805","article-title":"Rheumatoid arthritis","volume":"322","author":"Harris","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.01.029_bib2","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","article-title":"Cytokine pathways and joint inflammation in rheumatoid arthritis","volume":"344","author":"Choy","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.01.029_bib3","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2165\/00003495-200262060-00003","article-title":"Newer immunosuppressive drugs","volume":"62","author":"Drosos","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.amjmed.2005.01.029_bib4","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjmed.2005.01.029_bib5","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2005.01.029_bib6","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.01.029_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjmed.2005.01.029_bib8","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjmed.2005.01.029_bib9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"suppl 2","key":"10.1016\/j.amjmed.2005.01.029_bib10","first-page":"32","article-title":"Management of refractory rheumatoid arthritis","volume":"38","author":"van de Putte","year":"1999","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.amjmed.2005.01.029_bib11","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2165\/00002512-200320100-00002","article-title":"Methotrexate intolerance in elderly patients with rheumatoid arthritis","volume":"20","author":"Drosos","year":"2003","journal-title":"Drugs Aging"},{"key":"10.1016\/j.amjmed.2005.01.029_bib12","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/ard.62.10.1023","article-title":"Definition of discontinuation of anti-tumour necrosis factor therapy in rheumatoid arthritis","volume":"62","author":"Braun","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.amjmed.2005.01.029_bib13","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/ard.61.9.793","article-title":"Etanercept, infliximab, and leflunomide in established rheumatoid arthritis","volume":"61","author":"Geborek","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.amjmed.2005.01.029_bib14","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1136\/ard.61.9.822","article-title":"Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis","volume":"61","author":"Temekonidis","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.amjmed.2005.01.029_bib15","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/rheumatology\/41.10.1109","article-title":"Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate","volume":"41","author":"Ferraccioli","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.amjmed.2005.01.029_bib16","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.10302","article-title":"The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis","volume":"46","author":"St Clair","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjmed.2005.01.029_bib17","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/rheumatology\/keg171","article-title":"Influence of therapy with chimeric monoclonal tumor necrosis factor \u03b1 antibodies on intracellular cytokine profiles of T lemphocytes and monocytes in rheumatoid arthritis patients","volume":"42","author":"Schuerwegh","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.amjmed.2005.01.029_bib18","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/keg263","article-title":"Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF therapy","volume":"42","author":"Kroesen","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.amjmed.2005.01.029_bib19","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjmed.2005.01.029_bib20","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0092-8674(89)90676-4","article-title":"The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection","volume":"56","author":"Kindler","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.amjmed.2005.01.029_bib21","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/IAI.69.3.1847-1855.2001","article-title":"Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis","volume":"69","author":"Mohan","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.amjmed.2005.01.029_bib22","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha\u2014neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.01.029_bib23","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/art.10876","article-title":"Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy","volume":"48","author":"De Rycke","year":"2003","journal-title":"Arthritis Rheum"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934305000720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934305000720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:37:50Z","timestamp":1757579870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934305000720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S0002934305000720"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2005.01.029","relation":{},"ISSN":["0002-9343"],"issn-type":[{"type":"print","value":"0002-9343"}],"subject":[],"published":{"date-parts":[[2005,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infliximab therapy in established rheumatoid arthritis: An observational study","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2005.01.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}